WaveMan · Form 4
Love Ted W insider trades
> Search tickers & screens ⌘K
LIVE

Love Ted W insider trades

Love Ted W has filed 28 Form 4s with the SEC that we hold, for GBT (President and CEO, Director), Royalty Pharma plc (RPRX) (Director), Gilead Sciences, INC. (GILD) (Director) and Structure Therapeutics Inc. (GPCR) (Director), among 6 companies in all. None of these filings reports a purchase (code P) or sale (code S) of common stock; they cover grants, option exercises and other codes. The first filing on our record is dated 2021-09-03 and the latest 2026-09-02.

GBT

President and CEO, Director · 9 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Royalty Pharma plc (RPRX)

Director · 5 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Gilead Sciences, INC. (GILD)

Director · 4 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Structure Therapeutics Inc. (GPCR)

Director · 4 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Jazz Pharmaceuticals plc (JAZZ)

Director · 3 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

SGEN

Director · 3 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1188919) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms